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were used to compare outcomes across satisfaction groups. Results: Only 64 (4.08%) 
were satisfied with their treatment, and 1504 (95.92%) not satisfied. A positive relation-
ship was observed between satisfaction and HRQoL, with the most satisfied group 
recording a 31.62% higher EQ-5D score (mean 0.75 vs. 0.57, p< 0.01) relative to the next 
most-satisfied group. A negative relationship was observed between satisfaction and 
pain, with the most satisfied patient group scoring 30.89% lower pain scores (mean 
3.40 vs. 4.91, p< 0.01). ConClusions: Most neuropathic pain patients are not satis-
fied with their current pain therapy. This analysis suggests a negative relationship 
between treatment satisfaction and reported pain severity as well as a clear positive 
relationship between treatment satisfaction and health related quality of life. The 
results highlight the need for a more targeted treatment of neuropathic pain patients.
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objeCtives: According to the Pain in Europe Study, about one in five EU adults 
have chronic pain. Back pain / lower back pain is among the most commonly cited 
location of pain.1 Additionally, research has suggested that pain has a negative 
impact on sufferer mental health, employment, sleep and personal relationships.2 
This analysis profiles and compares adults experiencing back pain to adults with-
out pain across 5EU. Methods: Results were taken from the 2011 5EU National 
Health and Wellness Survey, a nationally representative, self-administered survey. 
Respondents were adults age 18 and over from France, Germany, Italy, Spain and 
UK. This analysis focuses on adults diagnosed with back pain or experienced pain 
as a result of back problem in the past month- (“patients with back pain”). Quality 
of life was measured using the SF12v2 scale. Activity impairment was measured 
using the Work Productivity and Activity Impairment scale. Results: Out of the 
total sample of n= 57,512, ~10% (n= 5,984) have back pain. Relative to adults without 
pain, back pain sufferers are older on average (48.9 vs. 46.3), more likely to be women 
(57% vs. 48%), and obese (27% vs. 16%). Their overall mental and physical quality of 
life scores are significantly lower (43.2 vs. 47.9, p < 0.001 and 40.3 vs. 50.9, p < 0.001). 
In addition, back pain sufferers are exhibited more work impairment (absenteeism 
and presenteeism) and activity impairment, and utilized health care resources to a 
greater extent than non-sufferers (i.e., greater physician visits, hospitalization, and 
ER). All these results are notably higher among back pain patients treated with a pre-
scription. ConClusions: Considering the prevalence of back pain among adults, 
the level of work impairment and quality of life limitations impacts a substantial 
portion of adults in the 5EU population. Improvements in treatment of back pain 
are needed to reduce this burden.
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objeCtives: Reversal of the residual effect of rocuronium or vecuronium by neostig-
mine may be slow and associated with side-effects. Sugammadex, a selective relaxant 
binding agent, encapsulates rocuronium to provide for a rapid reversal of residual 
neuromuscular blockade. Also, postoperative residual neuromuscular block can 
reduce delay of awakening, recovery, and dissatisfaction of patient. The aim of this 
study is to evaluate the willingness-to-pay (WTP) of sugammadex for effectiveness 
and safety using a contingent valuation method. Methods: A total of 505 adult 
general population and 60 experts (anesthesiologist and surgeon) participated in 
a face-to-face survey. The respondents were surveyed separately each scenario of 
moderate and deep blocks for surgery. The scenario was designed to provide informa-
tion concerning reversal time on neuromuscular block, adverse reaction of PRNB, and 
quality of surgery or recovery. The out-of-pocket WTP for sugammadex was utilized 
open answer. Results: In general population, WTP values for sugammadex were 
81,768 Korean won (KRW) in moderate block and 128,622 KRW in deep block. The same 
sample answered 89,017 KRW and 141,536 KRW for WTP for their family members 
in moderate block and deep block, respectively. Experts were estimated the WTP of 
99,417 KRW in moderate block and 153,250 KRW in deep block. For patients, experts 
suggested that 82,517 KRW and 132,517 KRW were appropriate WTP. The WTP was sta-
tistically significantly higher in the general population who had been taken operation 
and older than their counterparts. ConClusions: The WTP for sugammadex was 
ranged the 81,768 to 99,417 KRW in moderate block, and the 128,622 to 153,250 KRW 
in deep block. The WTP of general population for their family members was higher 
than the WTP for their own, and the expert’s WTP was higher than their patients.
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objeCtives: To assess rheumatologist perception towards biosimilars and the 
likelihood of use of biosimilars to manage RA patients in the EU, Brazil, Japan and 
China. Methods: A multi-country cross-sectional survey was conducted in top-5 
EU countries (UK/Germany/Spain/France/Italy), Brazil, Japan and China in April/
May 2013 using an online physician panel in the respective geographies; rheu-
matologists were randomly selected for survey participation to be geographically 
representative in select countries/regions. Surveys assessed the rheumatologist 
perceptions of biosimilars in terms of factors that would prevent them from using 
RS6:43.7;28.5,60.0)+(NPRS7: 46.3;31.1,61.5)+(NPRS8: 58.5;42.6,74.4)+(NPRS9:2.0;44.2,
79.8)+(NPRS10:72.2;54.7,89.7). The estimated marginal mean WPAI-NP-AI increased 
linearly from 10.1% at NPRS 0 to 84.8% at NPRS 10. Predicted WPAI-NP-AI was highly 
correlated with observed values (R-squared= 0.889); mean absolute error (predicted-
observed) was 9.6 (sd 6.9). ConClusions: In people with chronic NP, increasing 
pain severity was associated with a linear increase in impairment of regular daily 
activities other than paid work. Interventions that reduce pain are likely to improve 
functioning.
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objeCtives: Bariatric surgery is the best long-term treatment for morbid obesity 
with clinical improves, like reductions in blood pressure, glucose and lipids levels. 
However postoperative complications and psychosocial issues may impact qual-
ity of life (QoL). This study aims to assess health-related quality of life (HRQoL) in 
Brazilian obese patients submitted to bariatric surgery. Methods: A systematic 
review was conducted by April 2013 through Cochrane Collaboration, Medline, 
EMBASE, and Lilacs databases. Studies that described QoL in Brazilian obese 
patients were included in this review. Bariatric Analysis and Reporting Outcome 
System (BAROS), Moorehead-Ardelt quality of life questionnaire II (M-A-QoLQII), 
Abbreviated WHOQoL questionnaire and Short Form-6D (SF-6D) were used to evalu-
ate the behavior of patients who underwent bariatric surgery in relation to QoL 
domains. Results: Seven studies met eligibility criteria. In all studies, individuals 
presented body mass index (BMI) ≥ 40kg/m2 or ≥ 35 kg/m2 associated with comor-
bidities. Patients reported their self-esteem (SE), physical activity (PA), social rela-
tions (SR), disposition to work (DW) and sexual activity (SA), after bariatric surgery. 
According to the M-A-QoLQII, three studies showed HRQoL improvement in 28.9%, 
39.5%, 28.4%, 30% and 25.6% of patients for SE, PA, SR, DW and SA, respectively. 
And 68.9%, 50.6%, 53.1%, 52.2%, 45.6% of patients guaranteed greatly improved 
regarding those parameters, respectively. After weight loss, bariatric surgery was 
effective to improve QoL in PA domain. Besides, when compared to patients submit-
ted to medical treatment, patients who underwent surgical procedure presented 
an improvement of 93% in HRQoL, contrasting with 65.4% of the medical cohort 
(p< 0.001). Only one study measured QoL before and after bariatric surgery: SF-36 
domains and M-A-QoLQII showed that post-surgery results were invariably better 
than pre-surgery ones (p< 0.001 for all domains). ConClusions: The present review 
demonstrated the potential QoL improvements in Brazilian patients after bariatric 
surgery, in addition to clinical benefits.
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objeCtives: To analyze the cost of therapy for patients with chronic myeloid 
leukemia (CML) and their quality of life. Methods: It is retrospective as regard 
to cost and prospective as regard to quality of life analysis. Five university hospi-
tals in four major cities treating all 320 CML-patients are included for the period 
2011-2012. Information is collected from the patients’ records about the health 
care resources used as medicines for CML, additional therapy, hospitalizations 
and physicians visits. The assessment of health related quality of life is con-
ducted with validated for the country SF-36 questionnaire. Results: A total of 
164 (51.2%) men and 156 (48.75%) women, average age 53.96±15.41 were observed. 
The average CML pharmacotherapy monthly cost is 5976.4 BGN, the average total 
pharmacotherapy cost for additional diseases is 566.27 BGN and the average addi-
tional costs for physicians’ visits and hospitalization is equal to 1504.69 BGN. The 
most expensive CML therapy is with Dasatinib 7771.20 BGN and the cheapest is 
Imatinib therapy equal to 5245.15 BGN. The most common additional diseases are 
cardiovascular (68%), followed by endocrine (29%). There is significant correlation 
between overall assessment for quality of life and average total additional costs 
– the higher assessment for QoL, the lower costs for hospitalization and visits. 
With the significantly highest score is the scale Bodily pain, followed by Physical 
functioning, and the lowest are Vitality, energy or fatigue and Role limitation. In 
most of patients on Imatinib (77.9%) are recorded good hematological responses 
and 66.7% are with major molecular response. ConClusions: CML is a disease 
consuming significant health care resources especially for major pharmacother-
apy with TKIs. Infrequent physicians’ visits and rarer hospitalizations generate 
higher assessment of quality of life.
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objeCtives: Neuropathic pain (NP) is a chronic progressive disease which is hard 
to control. This analysis investigates patients’ satisfaction with pain therapy and its 
relationship with pain severity and health related quality of life (HRQoL). Methods: 
Data were drawn from the 2012 Adelphi NP Disease Specific Programme, a cross-
sectional study involving 413 primary care physicians and specialists across Europe. 
Physicians provided detailed records for 3956 NP patients, of which 1568 patients 
voluntarily completed EQ-5D and Brief Pain Inventory questionnaires. HRQoL was 
measured via the EQ-5D, satisfaction via a three-option question answered by the 
patient, and pain via the Brief Pain Inventory (BPI) interference score. Boxplot analyses 
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objeCtives: To assess the treatment patterns and current disease severity of 
patients with PsO receiving their first biologic in 5EU, namely, UK, Germany (DE), 
France (FR), Italy (IT) and Spain (SP). Methods: A multi-country multi-center 
medical chart-review study of PsO patients was conducted among dermatologists 
in hospitals/private practices to collect de-identified data on patients who were 
recently treated with a biologic as part of usual care. Physicians were screened 
for practice-duration (3-30 yrs) and patient-volume (incl.> 2PsO biologic patients/
month) and recruited from a large panel to be geographically representative in 
each country. Physicians abstracted charts of next five consecutive biologic patients 
within each center/practice. Physicians abstracted patient diagnosis, treatment pat-
terns/dynamics and patient symptomatology/disease severity. Results from patients 
on first biologic treatment were analyzed. Results: In 4Q2012, 225 physicians 
abstracted 924 eligible PsO patient charts; 690 (75%) were on their first biologic 
(mean-age:46.9yrs, female:36%). Geographic distribution-UK:18%, DE:21%, FR:19%, 
IT:21%, SP:21%. Time-to-1st biologic from diagnosis (months)/time-on-current bio-
logic (months) varied- UK:140/17, DE:119/10, FR:138/15, IT:103/18, SP:127/17. Top-4 
first-line biologic treatments observed were etanercept, adalimumab, infliximab 
and ustekinumab. Treatment experience prior to first biologic varied dramati-
cally (not mutually exclusive): Immunomodulators-UK:92%,DE:51%,FR:68%,IT:73
%,SP:76%; phototherapy-UK:55%,DE:71%,FR:59%,IT:32%,SP:37%; topicals-UK:41%
,DE:69%,FR:46%,IT:43%,SP:39%; retinoids-UK:29%,DE:30%,FR:34%,IT:42%,SP:40%; 
fumerates-UK:13%,DE:69%,FR:0%,IT:1%,SP:0%; corticosteroids-UK:2%,DE:32%,
FR:10%,IT:14%,SP:10%; Average # of flares in the past yr were: UK-1.0,DE-1.3,FR-
1.1,IT-1.0,SP-1.6. Mean current PASI scores were: UK-8,DE-20,FR-12,IT-18,SP-11. 
Current disease severity per physician judgment was (remission/mild/moder-
ate/severe): UK-45%/25%/20%/10%, DE-26%/19%/21%/35%, FR-42%/34%/15%/9%, 
IT-39%/19%/31%/11%, SP-44%/29%/26%/2%. Mean number of treatments prior to 
first biologic varied by current disease severity (remission/mild/moderate/severe): 
UK-2.7/3.1/2.6/3.1, DE-3.0/3.7/2.7/4.1, FR-2.2/2.6/2.2/2.4, IT-2.2/2.2/2.3/2.1, SP:2.4/2.
2/2.3/2.3. ConClusions: Among PsO patients receiving their first biologic, treat-
ment patterns and disease severity varied across 5EU, with patients in Germany 
disproportionately experiencing higher disease burden. Factors influencing the 
observed variations in care and optimal therapeutic approaches (including treat-
ment sequencing) aligned with clinical guidelines to decrease patient disease bur-
den warrants scrutiny.
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objeCtives: In the Czech Republic there are three modern molecules available for 
the treatment of multiple myeloma: bortezomib, thalidomide and lenalidomide. 
In order to better understand this evolving specific market, analysis of consump-
tion trends has been conducted with emphasis on the molecules’ mutual influ-
ence. Methods: Time-consumption curves of bortezomib, lenalidomide and 
thalidomide since 2009, based on the economic data of the General Health Insurance 
Company of the Czech Republic, were analyzed. While there was reimbursement for 
thalidomide in the first line treatment and bortezomib in the second line in 2009, 
we focused on and evaluated the impact of the launch of lenalidomide in 2009 (as 
a second line treatment). We also investigated the extension of reimbursement of 
bortezomib for the use in the first line in 2010. Results: The introduction of lena-
lidomide (2009) led to a rapid decline in thalidomide consumption within the next 
year, in contrast to bortezomib, the consumption of which appeared unaffected. 
Furthermore, also the consumption of thalidomide decreased profoundly following 
the extension of reimbursement conditions of bortezomib (2010). The overall relative 
reduction in thalidomide consumption observed within the two years between 2009 
and 2011 was 70%. ConClusions: The presented retrospective analysis shows that 
the impact of myeloma treatment on payers’ financial budgets has increased nearly 
3-times in the last four years. The extension of reimbursement of bortezomib had a 
clear impact on the consumption of thalidomide, which was its supposed compara-
tor in the first line therapy. However, it appears that even though the introduction 
of lenalidomide did also significantly affect the consumption of thalidomid, it had 
no apparent impact on the use of bortezomib.
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objeCtives: To determine the prescribing and cost of appetite suppressants in a 
defined private sector patient population, as well as the prescribing of other medi-
cines to the patient sample. Methods: A retrospective drug utilisation study was 
conducted on a medical insurance claims database in South Africa for 2010 and 
2011. No clinical information was available in the database. Results: In 2010, 37 
patients (86.49% females) were prescribed 44 appetite suppressants at a total cost 
of R9813.39, of which 75.0% were for phentermine. The average age of patients 
was 40.95 (SD= 12.37) years. In 2011, 27 patients (77.78% females) received 42 pre-
scriptions for appetite suppressants at a total cost of R9967.73. The average age of 
patients was 40.04 years (SD= 10.41) (females: 37.95 (SD= 7.76) years; males 47.33 
(SD= 10.52) years). Most products (80.95%) were for phentermine, followed by d-norp-
seudoephedrine (14.29%) and diethylpropion (4.76). Prescribing patterns in 2010 
and 2011 were similar. Appetite suppressants are strictly regulated in South Africa. 
biosimilars among their biologic-eligible RA patients, and their likelihood of use of 
biosimilars. Descriptive statistics are reported. Results: A total of 173 rheuma-
tologists participated in the survey. Years of experience practicing rheumatology 
was: < = 1yr:0%, 2-5yrs:6%, 6-10yrs:17%, 11-20yrs:42%, > 20yrs:32%. Geographic dis-
tribution of rheumatologists was: 5EU-58%, Brazil-23%, Japan-11% and China-9%. 
Mean RA patient-volume/year was 291 (5EU-329, Brazil-259, Japan-232 and China-
189). Overall, 47% of rheumatologists reported that they would prescribe a biosimi-
lar to their eligible RA patients “definitely or highly likely” (5EU:58%, Brazil:21%, 
Japan:47%, China:47%); 51% of rheumatologists reported that they would try using 
biosimilars for 1-2 yrs among a small group of patients in their practice before 
starting to use it in a majority of biologic-eligible RA patients in their practice 
(5EU:60%, Brazil:33%, Japan:42%, China:47%). The top-5 factors that would prevent 
them from using biosimilars were diverse across the countries (Overall/5EU/Brazil/
Japan/China): Doubts in similarity to original molecule 60%/63%/67%/47%/33%), 
inadequate safety/efficacy profile/data (53%/51%/51%/58%/60%), lack of long-term 
data (46%/51%/41%/32%/40%), lack of national guidelines recommending the use 
of biosimilars (37%/39%/31%/32%/47%) and lack of data from local country/market 
(31%/23%/41%/42%/47%). ConClusions: Across markets, over half of the rheu-
matologists expressed concerns/reservations towards prescribing biosimilars to 
their eligible RA patients. While payer organizations look to biosimilars to contain 
costs and make medicines more affordable to RA patients in need, potential bar-
riers to biosimilar adoption may exist.
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objeCtives: Biologic therapy is increasingly used to treat autoimmune dis-
orders in developed markets, but usage is still low in emerging markets. This 
analysis was conducted to identify factors associated with current use of bio-
logic medication among patients with autoimmune disorders in emerging mar-
kets. Methods: Data were from the Brazil, China, and Russia National Health 
and Wellness Surveys, cross-sectional surveys representative of the total adult 
population (Brazil) or urban adult population (China and Russia) in each country, 
conducted in 2011 and 2012. Respondents self-reporting physician diagnosis of 
ankylosing spondylitis, Crohn’s disease, psoriasis, psoriatic arthritis, rheumatoid 
arthritis, or ulcerative colitis and using a prescription medication (Rx) for at least 
one of those conditions were included; patients with missing data for any covari-
ate were excluded. Binomial logistic regression included the following predictors: 
age, sex, country, income, Charlson Comorbidity Index (CCI), body mass index 
(BMI), monthly out of pocket (OOP) costs for Rxs, fear of needles, condition severity, 
length of diagnosis, and type of treating physician. Results: Of 1,507 respondents 
included in the analysis, 300 (19.9%) were using a biologic. Of those, 82.0% (n= 246) 
were in China. Relative to China, patients were less likely to use biologics in Brazil 
(OR 0.21; 95% CI: 0.13, 0.36) and Russia (OR: 0.29, 95% CI: 0.18, 0.46; ps< 0.001). Higher 
CCI was associated with use of biologics (OR: 1.18, 95% CI: 1.10, 1.26; p< 0.001), 
as were higher OOP costs (OR: 2.37, 95% CI: 1.04, 5.42; p< 0.05) compared to no 
OOP costs. Fear of needles was positively associated with biologic use (OR: 1.57, 
95% CI: 1.18, 2.09; p< 0.01). No other covariates were significant. ConClusions: 
Country was by the strongest predictor of biologic use in patients with autoim-
mune conditions in emerging markets, but higher costs and more comorbidities 
were associated with biologic use across emerging markets.
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objeCtives: To compare the disease status, treatments and outcomes of patients 
with AS receiving their first biologic in UK, Germany, France, Italy and Spain (5EU) 
with the US. Methods: A multi-country multi-center medical chart-review study 
of AS patients was conducted between October-December 2012 among physicians 
(rheumatologists: 5EU: 97%, US: 99%) in hospitals and private practices to collect 
de-identified data on AS patients who were recently treated with a biologic as 
part of usual care. Physicians were screened for duration of practice and patient 
volume and recruited from a large panel to be geographically representative in 
each country. Eligible AS patient charts (> 2) were randomly selected from a sample 
of prospective patients visiting each center/practice during the screening period. 
Physicians abstracted patient diagnosis, treatment patterns/dynamics and patient 
symptomatology/disease status/outcomes. Results: Seven hundred and ninety 
seven eligible AS patient charts (5EU:613, US: 184) were abstracted; 701 (5EU:549, 
US: 152) patients were on their first biologic (mean-age: 5EU:42.5yrs/US:42.4yrs; 
female: 5EU:16.2%/US:17.1%). Time-to-1st biologic from diagnosis (5EU:55.3months/
US:46.8months) and time-on-current biologic (5EU:31.7months/US:44.3months) 
differed between regions. Top-2 biologic treatments observed were – adalimumab 
(5EU:43%/US:35%) and etanercept (5EU:30%/US:41%). Among the top-3 reasons for 
biologic treatment initiation, ‘mechanism of action’ & ‘improve signs/symptoms’ 
were observed in both 5EU and US, whereas ‘positive personal experience’ (5EU) and 
‘prevention of structural damage’ (US) were also observed. Key lab measures docu-
mented were: ESR (5EU:17.4mm/h, US:20.9mm/h) and CRP (5EU:8.8mg/dl, US:2.7mg/
dl). Current disease severity per physician-judgment (mild:moderate:severe) was: 
5EU-63%:32%:6%, US-62%:34%:5%. Among patients with available data, current HAQ 
(5EU:1.3, US:0.8), BASDAI (5EU:2.9, US:3.4), VAS provider score (5EU:2.9, US:2.5), VAS 
patient score (5EU:3.0, US:2.7), Swollen Joint Count (5EU:1.3, US:0.5), and Tender Joint 
Count (5EU:2.0, US:0.9) differed across regions. ConClusions: Among AS patients 
receiving their first biologic, disease severity differed between 5EU and US, with 
patients in 5EU with relatively higher burden and poorer outcomes.
